Lexaria Bioscience Corp. 8-K Summary
Business Context and Reporting Period
Lexaria Bioscience Corp. (Nevada) filed this Current Report on Form 8-K on December 2, 2011, regarding events occurring on December 1, 2011. The company is headquartered in Vancouver, British Columbia, Canada.
Key Financial Metrics and Transaction Details
The filing reports a private placement offering of convertible debentures with the following terms:
- Total Proceeds: US$200,000
- Interest Rate: 12% per annum (simple basis)
- Maturity Date: December 1, 2012
- Conversion Price: US$0.35 per unit (1 common share + 1 warrant)
- Warrant Exercise Price: US$0.40 per share
- Security: Obligations are secured by certain company assets via a general security agreement.
The filing does not provide specific data on revenue, profit, cash flow, margins, or existing debt levels outside of this new obligation.
Material Changes and Issuance Details
The company issued the debentures to two insider subscribers:
- US Person: Mr. David DeMartini (issued under Rule 506 Regulation D exemption).
- Non-US Person: CAB Financial Services Ltd. (issued under Regulation S exemption).
The securities were not registered under the Securities Act of 1933 and cannot be offered or sold in the United States without registration or an applicable exemption.
Outlook, Risks, and Contingencies
The filing does not contain forward-looking guidance, management commentary on future operations, or a discussion of general risk factors. The primary contingency noted is the forced conversion provision set out in the convertible debenture certificate.
Key Facts for Investor Verification
- Verify the impact of the 12% interest expense on the company's cash burn rate.
- Confirm the specific assets pledged under the general security agreement.
- Assess the dilution potential upon conversion at US$0.35 and warrant exercise at US$0.40.
- Review the company's current liquidity position to ensure ability to service the debt if conversion does not occur by maturity.